Chemical compounds
The invention concerns compounds of Formula (I) or pharmaceutically-acceptable salts thereof, wherein R 1 to R 5 have any of the meanings defined hereinbefore in the description: processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of cell proliferative disorders.
1. A compound of the Formula (I)
wherein:
R 1 and R 2 are each independently H or F;
R 3 is H or methyl; and
either:
a) R 4 is H and R 5 is F; or
b) R 4 is F and R 5 is H;
or a pharmaceutically-acceptable salt thereof.
2. A compound as claimed in claim 1 , or a pharmaceutically-acceptable salt thereof, wherein the compound is a compound of formula (IA)
3. A compound as claimed in claim 1 , or a pharmaceutically-acceptable salt wherein R 3 is hydrogen.
4. A compound as claimed in claim 1 , or a pharmaceutically-acceptable salt thereof wherein R 3 is methyl.
5. A compound as claimed in claim 1 , or a pharmaceutically-acceptable salt thereof wherein R 4 is hydrogen and R 5 is fluoro.
6. A compound as claimed in claim 1 , or a pharmaceutically-acceptable salt thereof wherein R 5 is hydrogen and R 4 is fluoro.
7. A compound as claimed in claim 1 or a pharmaceutically-acceptable salt thereof which compound is selected from:
(E)-3-(3,5-difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(3,5-difluoro-4-((1R,3R)-2-((S)-3-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(4-((1R,3R)-2-((S)-3-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(3,5-difluoro-4-(2-((S)-3-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(3,5-difluoro-4-(2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(4-(2-((S)-3-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(4-(2-(2-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid;
(E)-3-(3-fluoro-4-(2-((S)-3-fluoro-2-methylpropyl)-3,3-dimethyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid; and
(E)-3-[4-[(1R,3R)-1-deuterio-2-(2-fluoro-2-methyl-propyl)-3-methyl-4,9-dihydro-3H-pyrido[3,4-b]indol-1-yl]-3,5-difluoro-phenyl]prop-2-enoic acid.
8. A compound as claimed in claim 7 , which is (E)-3-(3,5-Difluoro-4-((1R,3R)-2-(2-fluoro-2-methylpropyl)-3-methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl)phenyl)acrylic acid, or a pharmaceutically-acceptable salt thereof.
9. A pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically-acceptable salt thereof, as claimed in claim 1 , and a pharmaceutically-acceptable diluent or carrier.
10. The compound of claim 8 .
11. The pharmaceutically acceptable salt of the compound of claim 8 .